Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 3
2005 4
2006 2
2007 4
2008 3
2009 7
2010 5
2011 8
2012 3
2013 7
2014 2
2015 4
2016 6
2017 2
2018 8
2019 6
2020 15
2021 7
2022 9
2023 15
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
PROTAC therapy as a new targeted therapy for lung cancer.
Li JW, Zheng G, Kaye FJ, Wu L. Li JW, et al. Among authors: zheng g. Mol Ther. 2023 Mar 1;31(3):647-656. doi: 10.1016/j.ymthe.2022.11.011. Epub 2022 Nov 22. Mol Ther. 2023. PMID: 36415148 Free PMC article. Review.
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.
Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim YM, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D. Khan S, et al. Among authors: zheng g. Nat Med. 2019 Dec;25(12):1938-1947. doi: 10.1038/s41591-019-0668-z. Epub 2019 Dec 2. Nat Med. 2019. PMID: 31792461 Free PMC article.
Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy.
Prasanna PG, Citrin DE, Hildesheim J, Ahmed MM, Venkatachalam S, Riscuta G, Xi D, Zheng G, Deursen JV, Goronzy J, Kron SJ, Anscher MS, Sharpless NE, Campisi J, Brown SL, Niedernhofer LJ, O'Loghlen A, Georgakilas AG, Paris F, Gius D, Gewirtz DA, Schmitt CA, Abazeed ME, Kirkland JL, Richmond A, Romesser PB, Lowe SW, Gil J, Mendonca MS, Burma S, Zhou D, Coleman CN. Prasanna PG, et al. Among authors: zheng g. J Natl Cancer Inst. 2021 Oct 1;113(10):1285-1298. doi: 10.1093/jnci/djab064. J Natl Cancer Inst. 2021. PMID: 33792717 Free PMC article.
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. Jia Y, et al. Among authors: zheng g. Haematologica. 2023 Oct 1;108(10):2626-2638. doi: 10.3324/haematol.2022.281915. Haematologica. 2023. PMID: 37078252 Free PMC article.
Piperlongumine conjugates induce targeted protein degradation.
Pei J, Xiao Y, Liu X, Hu W, Sobh A, Yuan Y, Zhou S, Hua N, Mackintosh SG, Zhang X, Basso KB, Kamat M, Yang Q, Licht JD, Zheng G, Zhou D, Lv D. Pei J, et al. Among authors: zheng g. Cell Chem Biol. 2023 Feb 16;30(2):203-213.e17. doi: 10.1016/j.chembiol.2023.01.004. Epub 2023 Feb 6. Cell Chem Biol. 2023. PMID: 36750097 Free PMC article.
Cellular senescence and radiation-induced pulmonary fibrosis.
He Y, Thummuri D, Zheng G, Okunieff P, Citrin DE, Vujaskovic Z, Zhou D. He Y, et al. Among authors: zheng g. Transl Res. 2019 Jul;209:14-21. doi: 10.1016/j.trsl.2019.03.006. Epub 2019 Mar 27. Transl Res. 2019. PMID: 30981698 Free PMC article. Review.
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy.
Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC, Liu Y, Maharjan CK, Patel UM, De U, Carelock ME, Tithi TI, Li X, Shaffer DR, Guertin KR, Zhuang H, Moser E, Smalley KSM, Lv D, Zhou D, Zheng G, Zhang W. Wang L, et al. Among authors: zheng g. J Exp Med. 2024 Mar 4;221(3):e20231519. doi: 10.1084/jem.20231519. Epub 2024 Feb 9. J Exp Med. 2024. PMID: 38334978 Free PMC article.
Overcoming Cancer Drug Resistance Utilizing PROTAC Technology.
Burke MR, Smith AR, Zheng G. Burke MR, et al. Among authors: zheng g. Front Cell Dev Biol. 2022 Apr 25;10:872729. doi: 10.3389/fcell.2022.872729. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35547806 Free PMC article. Review.
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
Lv D, Pal P, Liu X, Jia Y, Thummuri D, Zhang P, Hu W, Pei J, Zhang Q, Zhou S, Khan S, Zhang X, Hua N, Yang Q, Arango S, Zhang W, Nayak D, Olsen SK, Weintraub ST, Hromas R, Konopleva M, Yuan Y, Zheng G, Zhou D. Lv D, et al. Among authors: zheng g. Nat Commun. 2021 Nov 25;12(1):6896. doi: 10.1038/s41467-021-27210-x. Nat Commun. 2021. PMID: 34824248 Free PMC article.
113 results